

9 February 2024

TrivarX to collaborate with Northern Michigan University (NMU) on sleep research programs

Highlights:

- TrivarX to collaborate with Northern Michigan University and utilise Stager as part of the University's ongoing sleep research programs
- Stager is TrivarX's AI-based software solution that provides rapid data metrics on the four key stages of sleep
- NMU is a highly credentialed, US university that has grown its reputation based on its cutting-edge technology initiatives and nationally recognised academic programs
- Project to target advancements in neurophysiological monitoring through the deployment of technology operated by NMU's Department of Psychological Sciences, supported by TRI's core competencies in proprietary statistical modelling and machine learning
- Agreement provides strong validation of TRI's Stager solution and marks the first deployment in TRI's ongoing beta program from the product
- Discussions with other potential partners are ongoing with more deployments pending

Perth, Australia, and Minneapolis, USA: TrivarX Limited ('the Company') (ASX: TRI) is pleased to advise it has entered into a data transfer agreement ("**agreement**") with the Department of Psychological Sciences at Northern Michigan University (NMU). Under the agreement, NMU and TrivarX will collaborate on sleep research programs where NMU will share sleep research data with the Company and TrivarX will provide NMU with specific metrics that Stager extracts from sleep data.

Northern Michigan University, located in Marquette, Michigan, is a dynamic, comprehensive university that has grown its reputation based on its award-winning leadership programs, cutting-edge technology initiatives and nationally recognised academic programs.

The collaboration follows extensive discussions between the parties to pursue research aimed at using novel and neurophysiological monitoring approaches for evaluating stress and other mental health conditions. The collaboration aims to leverage the strengths of both NMU and TrivarX to pursue new approaches to neuromonitoring solutions, building from the university's decades of research experience using sophisticated neuromonitoring techniques.

These include NMU's recent acquisition of a high-density electroencephalography (EEG) system for measuring affective states, particularly those associated with stress, anxiety, and depression. In turn, the University selected TrivarX as a research partner due to the Company's experience with mental health conditions and understanding of how sleep may play a critical role in the diagnosis of them.

As part of the collaboration, NMU will deploy TrivarX's proprietary sleep research software, Stager – a unique AI-based software solution that provides researchers with new and improved data metrics in sleep studies – as part of its ongoing sleep study program.

In collaborating with TrivarX, NMU will advance a joint investigation to monitor brain activity during sleep and heart rate variability. The collaboration has the potential to unlock breakthroughs relating to the role of brain activity during sleep and the level and type of mental illness, potentially including predictors of the onset of mental disorders.

ASX ANNOUNCEMENT



TrivarX expects that the findings from academic research will assist with ongoing product development to further diversify its solutions and increase industry awareness of Stager. The agreement marks the first deployment of Stager's beta program. The Board and management are in discussions with a number of parties regarding additional agreements and will provide updates as these materialise.

Term and Termination

Apart from standard provisions of termination for non-conformance, this Agreement may be terminated by either Party giving to the other Party a minimum of thirty (30) days prior written notice. Upon termination or expiration of this Agreement, TrivarX will retain the rights to use all data for further research and product development. The specific metrics and insights provided by TrivarX to NMU, are not to be shared by NMU with external parties for the purpose of developing any behavioural health algorithms or products, without advance notice and written authorisation from TrivarX (within the sole discretion of TrivarX). In exchange for this restriction, TrivarX will continue to provide research support in terms of data metrics and research resources including discretionary financial support to continue the research partnership. The Board and management does not expect this agreement to have a material impact on the Company's financial position.

Management commentary:

Adam Prus, Distinguished Professor and Department Head of Psychological Sciences at Northern Michigan University said: *"TrivarX's extensive experience using advanced and proprietary statistical models and machine learning using real-world applications provides unique opportunities for pursuing novel research questions that are beyond present capabilities."*

"In short, from our perspective, our relationship with TrivarX gives us access to a group of highly trained, scientifically-rigorous professionals that clearly see the link between basic research and the application of the research findings for product development. The TrivarX collaboration significantly enhances our climate for research and education. We look forward to continuing to grow this collaboration for many years to come."

TrivarX Chief Medical officer, Archie Defillo, MD said: *"This research collaboration reflects the strength of the recently established relationship between TrivarX and NMU, which both share a commitment to finding improved neuromonitoring solutions through best-in-class research and development practices."*

"We are excited to combine TrivarX's inherent strengths in AI, statistical modelling and machine learning with the depth of experience and expertise of NMU's leading neurophysiology researchers."

"We expect this collaboration to be uniquely beneficial for both parties, with the capacity to unlock significant research breakthroughs directly related to our field of commercial development. Further, TrivarX will also benefit from increased industry awareness around our product and ongoing feedback from NMU personnel regarding its use in their ongoing research initiatives."

This announcement is authorised for release by the Board of Directors of TrivarX Limited.

ENDS

Investor Enquiries:

Henry Jordan – Six Degrees Investor Relations
Henry.jordan@sdir.com.au
+61 431 271 538

ASX ANNOUNCEMENT



About TrivarX Limited:

TrivarX (ASX: TRI) (OTCPINK: MDBIF) is a mental health technology company pioneering the use of objective measures to aid in the early detection and screening of mental health conditions. Through their Corporate Health product, the Company offers mental well-being solutions for businesses and are also developing products to serve the healthcare provider market. The Company was founded in Australia, with offices located in Perth (WA) and Minneapolis (MN, USA). TrivarX is listed on the Australian Securities Exchange Ltd and trades on the OTCQB Venture Market. Investors can find additional information on www.otcm Markets.com and www.asx.com.au.

For personal use only